Evidence map›Paper›PMID 42132421›Full record

ArticleJournal of virology2026

Longitudinal analysis of viral and host RNA in blood and saliva during controlled human dengue virus 3 infections.

Sharon S Wu, Jennifer N Bjerke, Casey E Middleton, Arturo Barbachano-Guerrero, Joshua R Dye, Emma R Worden-Sapper, Amy B Emerman, Timothy P Endy, Stephen J Thomas, Adam T Waickman and 3 more

Registry-linked trialAbstract read
In one paragraph

Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04298138 (Phase One, Open Label Assessment of a Dengue-3-Virus-Live Virus Human Challenge -), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04298138 phase1completednot on this map

Phase One, Open Label Assessment of a Dengue-3-Virus-Live Virus Human Challenge - (DENV-3-LVHC) Virus Strain

TypeinterventionalSponsorState University of New York - Upstate Medical UniversityRan2020 to 2021Enrolled9ConditionsDengueArmsDengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sharon S WuDepartment of Molecular, Cellular, and Developmental Biology, University of Colorado Boulder, Boulder, Colorado, USA.ORCID 0000-0003-4883-9625
Jennifer N BjerkeDarwin Biosciences, Boulder, Colorado, USA.
Casey E MiddletonBioFrontiers Institute, University of Colorado Boulder, Boulder, Colorado, USA.
Arturo Barbachano-GuerreroDepartment of Molecular, Cellular, and Developmental Biology, University of Colorado Boulder, Boulder, Colorado, USA.
Joshua R DyeDarwin Biosciences, Boulder, Colorado, USA.
Emma R Worden-SapperDepartment of Molecular, Cellular, and Developmental Biology, University of Colorado Boulder, Boulder, Colorado, USA.
Amy B EmermanDarwin Biosciences, Boulder, Colorado, USA.
Timothy P EndyGlobal Health Institute, State University of New York Upstate Medical University, Syracuse, New York, USA.
Stephen J ThomasGlobal Health Institute, State University of New York Upstate Medical University, Syracuse, New York, USA.
Adam T WaickmanGlobal Health Institute, State University of New York Upstate Medical University, Syracuse, New York, USA.ORCID 0000-0002-4536-6714
Daniel B LarremoreBioFrontiers Institute, University of Colorado Boulder, Boulder, Colorado, USA.
Nicholas R MeyersonDarwin Biosciences, Boulder, Colorado, USA.
Sara L SawyerDepartment of Molecular, Cellular, and Developmental Biology, University of Colorado Boulder, Boulder, Colorado, USA.ORCID 0000-0002-6965-1085

Funding

Breaking the Barrier to an HIV VaccineDP1AI175471 · NIAID · UNIVERSITY OF COLORADO · PI Sara Sawyer · 2022 to 2026
$5.5M
Hunting the HIV-1 UnicornDP1DA046108 · NIDA · UNIVERSITY OF COLORADO · PI SAWYER, SARA · 2018 to 2022
$4.5M
Characterizing Host-Virus Interactions in a New HIV Model OrganismR01OD034046 · OD · UNIVERSITY OF COLORADO · PI Sara Sawyer · 2022 to 2026
$3.6M
NIAID NIH HHS DP1 AI175471NIDA NIH HHS DP1 DA046108NIH HHS R01 OD034046
6 · The paper itself

Abstract

Dengue viruses are mosquito-borne human pathogens whose global incidence in human infections is rising. Surveillance is hampered by the requirement for blood-based diagnostics. Interestingly, in several prior research studies, dengue virus nucleic acids and proteins could be detected in saliva, making saliva-based diagnostics a plausible alternative. However, the temporal relationships between exposure, viremia, salivary accumulation, and symptom onset remain poorly defined. To address this knowledge gap, nine participants were enrolled in clinical trial NCT04298138 to receive an inoculation with an attenuated dengue virus (DENV-3 strain CH53489). Matched blood and saliva specimens were collected over 10 days. Dengue virus genomes could be detected by RT-qPCR in both blood and saliva before the onset of symptoms in most individuals. The earliest time of detection in blood and saliva was 3.4 and 5.0 days post-infection, respectively. Using this sample set, we also measured host transcriptional responses to dengue infection in both biospecimens. Strikingly, far more human genes showed increased transcript abundance exclusively in saliva (14%) than in PBMCs (5%) or both compartments simultaneously (6%), revealing compartment-specific host responses. For 21 of the human transcripts that increased in response to dengue infection, we quantified their daily abundance across the course of DENV-3 infection in all study participants. Together, these findings demonstrate that sensitive dengue virus detection in saliva should be possible and establish that both blood and saliva capture early host responses to infection.IMPORTANCEDengue virus infections are detected using blood samples, either with nucleic acid amplification tests for the dengue virus genome (in the case of an active infection) or serology-based tests for antibodies recognizing dengue viruses (indicating a prior infection). The requirement for blood draws creates a barrier to dengue virus surveillance. Our data demonstrate that saliva can serve as an alternative biospecimen for detecting dengue virus genomes early in infection, with detection lagging blood by only 1.6 days-a modest and likely acceptable tradeoff given saliva's practical advantages. Unlike blood, saliva is non-invasive, self-collectible, requires no sharps, and is thermostable. We also identified host genes upregulated upon dengue infection, informing on the host response to infection. Our longitudinal study design enabled us to track the kinetics of transcript accumulation both by day post-infection and relative to symptom onset, providing high resolution into the host response to the virus.CLINICAL TRIALSThis study is registered with ClinicalTrials.gov as NCT04298138.

Indexed as

DengueDengue VirusRNA, ViralSalivaAdultFemaleHuman Challenge Trials as TopicHumansLongitudinal StudiesMaleViremiaRNA, Viraldengue virushost response

Identifiers

PMID42132421
PMCPMC13289089

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.